<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478542</url>
  </required_header>
  <id_info>
    <org_study_id>DSHNHL 2009-1</org_study_id>
    <nct_id>NCT01478542</nct_id>
  </id_info>
  <brief_title>OPTIMAL&gt;60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine</brief_title>
  <acronym>OPTIMAL&gt;60</acronym>
  <official_title>Improvement of Outcome and Reduction of Toxicity in Elderly Patients With CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET Based Reduction of Therapy in Combination With Vitamin D Substitution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German High-Grade Non-Hodgkin's Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve the outcome of elderly patients with CD20+ Aggressive
      B-Cell Lymphoma and to reduce the toxicity of standard used Immuno-Chemotherapy by using an
      optimised schedule of the monoclonal antibody Rituximab, substituting conventional by
      Liposomal Vincristine and by a PET-guided reduction of therapy in Combination with Vitamin D
      Substitution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective of study:

      &quot;OPTIMAL&gt;60 Less Favourable&quot; Patients with less favourable prognosis:

      To test whether progression-free survival (PFS) can be improved by substituting conventional
      by liposomal vincristine;

      To test whether PFS can be improved by 12 optimised applications instead of 8 2-week
      applications of rituximab.

      &quot;OPTIMAL&gt;60 Favourable&quot;: Patients with favourable prognosis:

      Comparison of neurotoxicity of conventional and liposomal vincristine;

      Determination of PFS for the treatment strategy of reducing treatment in patients with
      negative FDG-PET after 4 x R-CHOP/CHLIP-14 (PET-4) and comparison with the corresponding
      patient population in RICOVER-60.

      Secondary objectives: &quot;OPTIMAL&gt;60 Favourable&quot; and &quot;OPTIMAL&gt;60 Less Favourable&quot;:

      Comparison of the prognostic value of a pre-treatment FDG-PET (PET-0) with conventional
      CT/MRT.

      Investigation of the prognostic value of different FDG-PET derived imaging biomarkers for
      lymphoma load (SUV, MTV, TLG).

      Comparison of the FDG-PET-based individualised treatment strategy in OPTIMAL&gt;60 with the
      fixed (pre-defined) treatment strategy in RICOVER&gt;60.

      Estimation of the vincristine-related neurotoxicity (&quot;OPTIMAL&gt;60 Less Favourable only, since
      vincristine related neurotoxicity is primary objective of the study in favourable patients)
      and other toxicities (all patients).

      Determination of the therapeutic efficacy of a Vitamin D substitution by comparing the first
      patients without Vitamin D substitution with patients with Vitamin D substitution.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>9 years</time_frame>
    <description>&quot;OPTIMAL&gt;60 Less Favourable&quot;: To test the effects of substitution of conventional by liposomal vincristine and of a 2-week applications of 8x rituximab by an optimised application of 12 x rituximab stratified log rank tests will be performed for each question (stratified for IPI-factors). Proportional hazard models will be used to investigate treatment interaction and to obtain estimates for the single treatment effects (HR) adjusting for the IPI-factors.
&quot;OPTIMAL&gt;60 Favourable&quot; Grade of neurotoxicity will be estimated and indicated with a 95% confidence interval (CI) separated to each type of vincristine. To investigate the 3-year PFS with 95% CI the Kaplan-Meier estimator will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>for efficacy: CR-rate, PR-rate, rate of primary progressions, relapse rate, EFS and OS; rate and CTC grades of PNP. Prognostic value of the FDG-PET derived imaging biomarkers for lymphoma load: SUV, MTV, TLG.</measure>
    <time_frame>9 years</time_frame>
    <description>Secondary endpoints: To analyze how (i. e. in which direction) and how often a pre-treatment FDG-PET-based assignment (PET-0) would have affected the assignment of a patient to a different stage, IPI risk group or treatment, respectively. The different FDG-PET derived imaging biomarkers for lymphoma load (SUV, MTV, TLG) will be analyzed for their relationship with CR-rate, PR-rate, rate of primary progressions, relapse rate, EFS, PFS and OS.
To compare the efficacy and side effects of the (post-induction therapy FDG-PET-based) individualised treatment strategy in OPTIMAL&gt;60 with the fixed (pre-defined) treatment strategy in RICOVER-60.
Rates and grades of polyneuropathy will be determined according to CTC-v4.03. Comparison of the patients without vitamin-D-substitution with patients receiving a vitamin-D-substitution.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">1152</enrollment>
  <condition>CD20+ Aggressive B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Favourable Prognosis F-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy with 4 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHOP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Favourable F-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with 4 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 2 mg/sqm, Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2 additional cycles of R-CHLIP-14 + 2xR plus additional involved-site radiotherapy, if FDG-PET negative only 4xR without radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Less Favourable LF-A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy with 6 cycles of R-CHOP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHOP-14 an interim restaging will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Less Favourable LF-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with 6 cycles of R-CHLIP-14 (Rituximab 375 mg/sqm, Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 2 mg/sqm, Predniso[lo]ne 100mg/d d1-5) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive 2xR plus additional radiotherapy to the initial bulky region, if FDG-PET negative only 2xR without radiotherapy. After 3xR-CHLIP-14 an interim restaging will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Less Favourable LF-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with 6 cycles of CHOP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, conventional Vincristine 1,4 mg/sqm [max. 2mg absolute], Predniso[lo]ne 100mg/d d1-5) combined with an optimized Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHOP-14 an interim restaging will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Less Favourable LF-D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with 6 cycles of CHLIP-14 (Cyclophosphamide 750 mg/sqm, Doxorubicin 50 mg/sqm, liposomal Vincristine 2 mg/sqm, Predniso[lo]ne 100mg/d d1-5) combined with an optimised Rituximab-schedule (375 mg/sqm, d-4, d-1, d1, d4, d14, d28, d42, d56, d91, d126, d175, d238) and then definitive (post-induction) restaging with FDG-PET. If FDG-PET positive additional radiotherapy to the initial bulky region, if FDG-PET negative omission of radiotherapy. After 3x CHLIP-14 an interim restaging will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Vincristine</intervention_name>
    <arm_group_label>Favourable Prognosis F-A</arm_group_label>
    <arm_group_label>Less Favourable LF-A</arm_group_label>
    <arm_group_label>Less Favourable LF-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Vincristine</intervention_name>
    <arm_group_label>Favourable F-B</arm_group_label>
    <arm_group_label>Less Favourable LF-B</arm_group_label>
    <arm_group_label>Less Favourable LF-D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ricover-scheme rituximab</intervention_name>
    <arm_group_label>Less Favourable LF-A</arm_group_label>
    <arm_group_label>Less Favourable LF-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>optimised rituximab-schedule</intervention_name>
    <arm_group_label>Less Favourable LF-C</arm_group_label>
    <arm_group_label>Less Favourable LF-D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: 61-80 years

          2. All risk groups (IPI 1-5)

          3. Diagnosis of aggressive CD20+ B-NHL, based on an excisional biopsy of a lymph node or
             on an appropriate sample of a lymph node or of an extranodal involvement. It will be
             possible to treat the following entities in this study as defined by the new WHO
             classification of 200870:

             B-NHL:

               -  Foll. lymphoma grade IIIb

               -  DLBCL, not otherwise specified (NOS)

                    -  common morphologic variants:

                         -  centroblastic

                         -  immunoblastic

                         -  anaplastic

                    -  rare morphologic variants

               -  DLBCL subtypes/entities:

                    -  T-cell/histiocyte-rich large B-cell lymphoma

                    -  primary cutaneous DLBCL, leg type

                    -  EBV-pos. DLBCL of the elderly

               -  DLBCL associated with chronic inflammation

               -  primary mediastinal (thymic) LBCL

               -  intravascular large B-cell-lymphoma

               -  ALK-positive large B-cell-lymphoma

               -  plasmoblastic lymphoma

               -  primary effusion lymphoma

               -  transformed indolent lymphoma secondary or simultaneous high grade
                  B-cell-lymphoma

               -  B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and
                  Burkitt lymphoma

               -  B-cell lymphoma, unclassifiable, with features intermediate between DLCBL and
                  Hodgkin lymphoma

          4. Performance status ECOG 0 - 2 after prephase treatment. The performance status of each
             patient must be assessed before the initiation and after the end of prephase treatment
             which, as experience has shown, can result in a significant improvement of the
             patient's performance status. The pre-treatment performance status which can range
             from ECOG 0 to ECOG 4 must be documented in the Staging CRF (see ISF); the performance
             status after the prephase treatment must be documented in the respective Prephase
             Treatment CRF (PT form: see ISF). A definition of the performance status is provided
             in Appendix 28.10.

          5. Written informed consent of the patient

          6. Contract of participation signed by the study centre and sponsor

        Exclusion Criteria:

          1. Already initiated lymphoma therapy (except for the prephase treatment)

          2. Serious accompanying disorder or impaired organ function (except when due to lymphoma
             involvement), in particular:

               -  heart: angina pectoris CCS &gt;2, cardiac failure e.g. NYHA &gt;2 and/or EF &lt;50% or
                  FS&lt;25% in nuclear medicine examination/echocardiography

               -  lungs: if respiratory problems are suspected the patient is to be excluded if the
                  resultant pulmonary function test shows FeV1&lt;50% or a diffusion capacity &lt;50% of
                  the reference values

               -  kidneys: creatinine &gt;2 times the upper reference limit

               -  liver: bilirubin &gt;2 times the upper reference limit, aspartate transaminase (AST,
                  SGOT) or alanine transaminase (ALT, SGPT) &gt;3 x institutional upper reference
                  limit

               -  uncontrollable diabetes mellitus (prephase treatment with predniso[lo]ne!)

          3. Platelets &lt;75 000/mm3, leukocytes &lt;2 500/mm3 (if not due to lymphoma)

          4. Known hypersensitivity to the medications to be used

          5. Known HIV-positivity

          6. Patients with severe impairment of immune defense

          7. Patients with constipation with imminent risk of ileus

          8. Chronic active hepatitis

          9. Poor patient compliance

         10. Simultaneous participation in other treatment studies or in another clinical trial
             within the last 6 months

         11. Prior chemo- or radiotherapy, long-term use of corticosteroids or anti-neoplastic
             drugs for previous disorder

         12. Other concomitant tumour disease and/or tumour disease in the past 5 years (except for
             localised skin tumors other than melanoma and carcinomas in situ of any other origin)

         13. CNS involvement of lymphoma (intracerebral, meningeal, intraspinal intradural) or
             primary CNS lymphoma

         14. Persistent neuropathy grade ≥2 (NCI CTC-AE v4.03) (unless due to lymphoma involvement)

         15. History of persistent active neurologic disorders grade &gt;2 including demyelinating
             form of Charcot-Marie-Tooth syndrome, acquired demyelinating disorders, or other
             demyelinating condition

         16. Pregnancy or breast-feeding women

         17. Active serious infections not controlled by oral and/or intravenous antibiotics or
             anti-fungal medication

         18. Any medical condition which in the opinion of the investigator places the subject at
             an unacceptably high risk for toxicities.

         19. MALT lymphoma

         20. Non-conformity to eligibility criteria

         21. Persons not able to understand the impact, nature, risks and consequences of the trial
             (including language barrier)

         22. Persons not agreeing to the transmission of their pseudonymous data

         23. Persons depending on sponsor or investigator

         24. Persons from highly protected groups. Pts. with CNS lymphoma should not be included in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael G. Pfreundschuh, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University, Saarland University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>DSHNHL Central Study Office</last_name>
    <phone>+4968411623084</phone>
    <email>DSHNHL@uks.eu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saarland University Hospital</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Held, PD Dr. med.</last_name>
      <phone>+4968411683084</phone>
      <email>gerhard.held@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Gerhard Held, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Marien Amberg, MVZ</name>
      <address>
        <city>Amberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg, Medizinische Klinik II</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. med. Brudler, Heinrich, Bangerter</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Reichert, Janssen</name>
      <address>
        <city>Aurich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow, Klinik für Innere Medizin III</name>
      <address>
        <city>Bad Saarow</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg, Med. Klinik V</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth, Medizinische Klinik IV</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité- Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik III</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johanniter Krankenhaus Bonn, Abteilung für Innere Medizin I</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Med. Klinik III</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städt. Klinikum Brandenburg, Med. Klinik II</name>
      <address>
        <city>Brandenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Diakonie-Krankenhaus Bremen</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Obst</name>
      <address>
        <city>Burgwedel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Marquard</name>
      <address>
        <city>Celle</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz, Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Coburg, V. Med. Klinik</name>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis Dres. Glados/Retzlaff/Zühlsdorf/Deuticke</name>
      <address>
        <city>Coesfeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital Dortmund, Med. Klinik II</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BAG Freiberg-Richter, Jacobasch, Wolf, Illmer</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Mohm, Prange-Krex</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Med. Klinik 5</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.-Antonius-Hospital Eschweiler, Hämatologie und Onkologie</name>
      <address>
        <city>Eschweiler</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen, Klinik für Gastroenterologie, Onkologie und Innere Medizin</name>
      <address>
        <city>Esslingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder), Abteilung f. Innere Medizin</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe-Universität Frankfurt, Hämatologie/Onkologie</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest Frankfurt, II. Med. Klinik</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Reiber</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Innere Medizin I</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda, Med. Klinik III</name>
      <address>
        <city>Fulda</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Josef-Hospital Gelsenkirchen, Onkologie und Hämatologie</name>
      <address>
        <city>Gelsenkirchen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Schliesser</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilhelm-Anton-Hospital Goch, Innere Medizin</name>
      <address>
        <city>Goch</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Kooperation Harz, Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Goslar</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald, Medizinische Universitätsklinik C, Hämatologie und Onkologie</name>
      <address>
        <city>Greifswald</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Gummersbach</name>
      <address>
        <city>Gummersbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Hämatologie und Onkologie</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Gütersloh</name>
      <address>
        <city>Gütersloh</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Hagen, St.-Marien-Hospital</name>
      <address>
        <city>Hagen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Rohrberg, Hurtz, Schmidt, Frank-Gleich</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg, Hämatologie/Onkologie</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatolog.-onkolog. Praxis Dres. Müller-Hagen, Bertram, Albertinen-Krankenhaus</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Praxis Altona (HOPA)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE), II. Med. Klinik und Poliklinik, Onkologie und Hämatologie</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Hannover-Siloah, Med. Klinik III</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover (MHH), Zentrum für Innere Medizin, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis MediProjekt</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Innere Medizin V</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreis Herford, Med. Klinik II</name>
      <address>
        <city>Herford</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Dres. Freier, Sievers</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus Hildesheim, Med. Klinik II</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KMT Klinik Idar-Oberstein</name>
      <address>
        <city>Idar-Oberstein</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin II</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres Hansen, Reeb</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe, II. Med. Klinik, Hämatologie/Onkologie/Infektionskrankheiten</name>
      <address>
        <city>Karlsruhe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GMP Dres Siehl, Söling</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rotes Kreuz Krankenhaus Kassel, Klinik für Interdisziplinäre Onkologie</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten-Oberallgäu, Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Kempten</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum Mittelrhein, Ev. Stift St. Martin, Innere Medizin</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Neise, Lollert</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Strauch</name>
      <address>
        <city>Kronach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Schmitz, Steinmetz, Severin</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität zu Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Holweide</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut, Med. Klinik I</name>
      <address>
        <city>Landshut</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Caritas Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Leer</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg Leipzig, Abteilung für internistische Onkologie/Hämatologie</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe-Lemgo, Med. Klinik II</name>
      <address>
        <city>Lemgo</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Paul Gerhardt Stift, Klinik für Innere Medizin II</name>
      <address>
        <city>Lutherstadt Wittenberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Lörrach</name>
      <address>
        <city>Lörrach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg, Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz, III. Med. Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mannheimer Onkologie Praxis, Dres. Brust, Plöger, Schuster, Hensel</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum, Klinik für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin</name>
      <address>
        <city>Mutlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria-Hilf Mönchengladbach, Innere Medizin I</name>
      <address>
        <city>Mönchengladbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GMP Dres Schröder/Sieg</name>
      <address>
        <city>Mülheim an der Ruhr</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern, Med. Klinik 3</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der Technischen Universität München, III. Med.Klinik</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres. Schick, Schmidt, Fromm, Wiesmeier, Schick, Galler, Klapthor</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum München Harlaching</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GMP Dres Kriebel-Schmitt, Pelz</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Dr. Ladda</name>
      <address>
        <city>Neumarkt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lukaskrankenhaus Neuss, Med. Klinik II</name>
      <address>
        <city>Neuss</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Esslingen, Klinikum Kirchheim-Nürtingen, Hämatologie, Internist. Onkologie und Palliativmedizin</name>
      <address>
        <city>Nürtingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Balló, Böck</name>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Offenburg-Gegenbach, Medizinische Klinik II</name>
      <address>
        <city>Offenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg, Hämatologie/Onkologie</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Dr. Hübner</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg, Klinik für Strahlentherapie und Internistische Onkologie</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis im MVZ 2 GmbH, Dr. H. Eimermacher</name>
      <address>
        <city>Olpe</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück, Med. Klinik III</name>
      <address>
        <city>Osnabrück</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paracelsus Krankenhaus Ruit, Kreiskliniken Esslingen gGmbH, Zentrum für Allgemeine Innere Medizin</name>
      <address>
        <city>Ostfildern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Paderborn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Baake, Leonhardt, Moegling, am Regio Klinikum Pinneberg</name>
      <address>
        <city>Pinneberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann, Klinik für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dres. Decker, Nonnenbroich, Herbrik-Zipp</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prosper-Hospital Recklinghausen, Med. Klinik I</name>
      <address>
        <city>Recklinghausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Regensburg, Klinik für Onkologie und Hämatologie</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg, Kreiskliniken Reutlingen GmbH</name>
      <address>
        <city>Reutlingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Riesa, Klinik für Innere Medizin II</name>
      <address>
        <city>Riesa</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Südstadt Rostock, Innere Medizin</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock, Abteilung Hämatologie/Onkologie, Klinik u. Poliklinik für Innere Medizin</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>GMP Dres Jacobs, Daus, Schmits</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ZAHO-Siegburg, Zentrum für ambulante Hämatologie und Onkologie Siegburg</name>
      <address>
        <city>Siegburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Stuttgart, Med. Klinik II</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein, Hämatologie/Onkologie</name>
      <address>
        <city>Traunstein</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier, I. Med. Abteilung</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Medizinische Klinik und Poliklinik, Onkologie, Hämatologie, Immunologie und Rheumatologie</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm, Innere Medizin III</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Katharinen Hospital Unna</name>
      <address>
        <city>Unna</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med. Versorgungszentrum Weiden, Abteilung für Onkologie</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis Dres med. Perker, Sandherr</name>
      <address>
        <city>Weilheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HSK Wiesbaden, Innere Medizin III</name>
      <address>
        <city>Wiesbaden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helios Klinkum Wuppertal, Med. Klinik I</name>
      <address>
        <city>Wuppertal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Praxis Würselen</name>
      <address>
        <city>Würselen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2011</study_first_submitted>
  <study_first_submitted_qc>November 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2011</study_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>Liposomal Vincristine (Marqibo)</keyword>
  <keyword>Optimised Rituximab</keyword>
  <keyword>Toxicity</keyword>
  <keyword>Elderly Patients</keyword>
  <keyword>FDG-PET</keyword>
  <keyword>Bulky Disease</keyword>
  <keyword>Radiation</keyword>
  <keyword>age &gt;60 years</keyword>
  <keyword>First line Therapy</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

